Skip to main content

Table 5 Adverse events in the two treatment groups

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Adverse event

Sorafenib group (n = 48)

TACE + sorafenib group (n = 56)

Grade I

Grade II

Grade III

Grade IV

Grade I

Grade II

Grade III

Grade IV

Hand-foot skin reactions, n (%)

25 (44.64%)

8 (14.29%)

3 (5.36%)

0

24 (42.86%)

3 (5.36%)

3 (5.36%)

0

Vomiting, n (%)

19 (33.93%)

5 (8.93%)

3 (5.36%)

0

26 (46.43%)

4 (7.14%)

1 (1.79%)

0

Diarrhea, n (%)

21 (37.50%)

4 (7.14%)

2 (3.57%)

0

23 (41.07%)

1 (1.79%)

1 (1.79%)

0

Fatigue, n (%)

10 (17.86%)

2 (3.57%)

0

0

8 (14.29%)

4 (7.14%)

0

0

Hypertension, n (%)

19 (33.93%)

3 (5.36%)

0

0

10 (17.86%)

2 (3.57%)

1 (1.79%)

0

Leucopenia, n (%)

5 (8.93%)

2 (3.57%)

0

0

4 (7.14%)

0

1 (1.79%)

0

Anemia, n (%)

5 (8.93%)

2 (3.57%)

0

0

4 (7.14%)

1 (1.79%)

2 (3.57%)

0

Thrombocytopenia, n (%)

3 (5.36%)

2 (3.57%)

2 (3.57%)

0

3 (5.36%)

4 (7.14%)

1 (1.79%)

0

Alopecia, n (%)

2 (3.57%)

1 (1.79%)

0

0

3 (5.36%)

0

1 (1.79%)

0

Gastrointestinal hemorrhage, n (%)

0

0

4 (7.14%)

0

2 (3.57%)

1 (1.79%)

2 (3.57%)

0

Hepatic encephalopathy, n (%)

2 (1.79%)

1 (1.79%)